Please login to the form below

Not currently logged in
Email:
Password:

Kala Pharma appoints Fovea founder Bernard Gilly to board

He previously formed the company that became Sanofi’s ophthalmology business

Dr Bernard Gilly, founder and CEO of Sanofi-owned Fovea, has joined the board of Kala Pharmaceuticals.

He brings years of experience in eye treatment to Kala, which is developing mucosal penetrating products in a number of ophthalmic diseases.

“Dr Gilly is a seasoned entrepreneur in the biotechnology industry having spent over 20 years building and investing in leading life science companies,” said Dr Guillaume Pfefer, Kala's president and CEO.

“His track record and expertise in the ophthalmology space is an invaluable addition to Kala as we advance our pipeline of transformative ophthalmic products into the clinic.”

Dr Gilly, along with Professor Jose Sahel and Pierre Belichard, set up Fovea in 2005. The company was acquired by Sanofi in 2009, becoming the French pharma firm's ophthalmology division.

Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.

He also served as a co-president and VP of R&D of Sanofi Pasteur and VP of R&D of BioMérieux.

His other entrepreneurial efforts include helping to found several biotech companies, including Domain Therapeutics, WebSurg, Kutexis, GenSight Biologicals, Pixium Vision and Enterome. He currently serves as chair at the latter three companies.

29th November 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....